Insider · CIK 0002010662
Hamid Khoja
officer
Files at FBLG (FibroBiologics, Inc.). First filing May 27, 2025, latest Mar 5, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$28k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
FBLG: FibroBiologics, Inc.
FBLGOct 9, 2026 · close 1.13
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | FibroBiologics, Inc. | $11k 30,000 shares | +96% | +67% from low-73% from high | |
| 25Weak | FBLGbuy FibroBiologics, Inc. | $17k 20,000 shares | +178% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | FBLG FibroBiologics, Inc. | AGrant or award Common Stock | +298,508 | $1.68 | $500k | 301,571 | 27 d ago |
| Sep 15, 2026 | FBLG FibroBiologics, Inc. | AGrant or award Warrant (Right to Buy)derivative | +298,508 | - | - | 298,508 | 27 d ago |
| Mar 4, 2026 | FBLG FibroBiologics, Inc. | POpen-market purchase Common Stock | +30,000 | $0.38 | $11k | 61,250 | Mar 5, 2026 |
| May 27, 2025 | FBLG FibroBiologics, Inc. | POpen-market purchase Common Stock | +20,000 | $0.84 | $17k | 31,250 | May 27, 2025 |
| Mar 26, 2025 | FBLG FibroBiologics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +189,000 | $0.00 | $0 | 189,000 | Mar 28, 2025 |
| Dec 27, 2024 | FBLG FibroBiologics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +176,200 | $0.00 | $0 | 176,200 | Dec 30, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.